Cryptosporidiosis - Pipeline Review, H1 2018

Cryptosporidiosis - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Cryptosporidiosis - Pipeline Review, H1 2018, provides an overview of the Cryptosporidiosis (Infectious Disease) pipeline landscape.

Cryptosporidiosis is an intestinal illness caused by a microscopic parasite called Cryptosporidium. Symptoms include watery diarrhea, dehydration, and lack of appetite, weight loss, fever, nausea and vomiting. Risk factors include contaminated water, animal handlers and parents of infected children.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Cryptosporidiosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Cryptosporidiosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cryptosporidiosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cryptosporidiosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Cryptosporidiosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cryptosporidiosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Cryptosporidiosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cryptosporidiosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cryptosporidiosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cryptosporidiosis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cryptosporidiosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cryptosporidiosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cryptosporidiosis - Overview
Cryptosporidiosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cryptosporidiosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cryptosporidiosis - Companies Involved in Therapeutics Development
AbbVie Inc
ioGenetics Inc
Novartis AG
Romark Laboratories LC
Cryptosporidiosis - Drug Profiles
clofazimine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DBAF-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPLAJ-1317 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KDU-731 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-131 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RM-5038 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDPK1 for Protozoal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cryptosporidiosis - Dormant Projects
Cryptosporidiosis - Discontinued Products
Cryptosporidiosis - Product Development Milestones
Featured News & Press Releases
Mar 14, 2018: Calibrs repurposed drug to treat non-viral diarrhea enters into a clinical trial
Feb 14, 2018: Novartis forms alliance to develop medicines for treating infectious diarrheal disease
May 31, 2017: Progress reported in global fight against diarrheal disease cryptosporidiosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development for Cryptosporidiosis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Cryptosporidiosis - Pipeline by AbbVie Inc, H1 2018
Cryptosporidiosis - Pipeline by ioGenetics Inc, H1 2018
Cryptosporidiosis - Pipeline by Novartis AG, H1 2018
Cryptosporidiosis - Pipeline by Romark Laboratories LC, H1 2018
Cryptosporidiosis - Dormant Projects, H1 2018
Cryptosporidiosis - Discontinued Products, H1 2018

List Of Figures

List of Figures
Number of Products under Development for Cryptosporidiosis, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

Cryptosporidiosis - Pipeline Review, H1 2018

Cryptosporidiosis - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Cryptosporidiosis - Pipeline Review, H1 2018, provides an overview of the Cryptosporidiosis (Infectious Disease) pipeline

USD 2000 View Report

Cryptosporidiosis - Pipeline Review, H2 2017

Cryptosporidiosis - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Cryptosporidiosis - Pipeline Review, H2 2017, provides an overview of the Cryptosporidiosis (Infectious Disease) pipeline

USD 2000 View Report

Rett Syndrome - Pipeline Review, H2 2018

Rett Syndrome - Pipeline Review, H2 2018The latest Pharmaceutical and Healthcare disease pipeline guide Rett Syndrome - Pipeline Review, H2 2018, provides an overview of the Rett Syndrome (Central Nervous

USD 2000 View Report

Binge Eating Disorder - Pipeline Review, H2 2018

Binge Eating Disorder - Pipeline Review, H2 2018The latest Pharmaceutical and Healthcare disease pipeline guide Binge Eating Disorder - Pipeline Review, H2 2018, provides an overview of the Binge Eating

USD 2000 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available